Results 231 to 240 of about 9,510 (271)
Some of the next articles are maybe not open access.
The American journal of cardiology, 1998
We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia. Niaspan, 0.5 to 3.0 g once a night at bedtime, was used alone or in combination with a statin (inhibitor of hydroxymethylglutaryl coenzyme A reductase),
J R, Guyton +5 more
openaire +1 more source
We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia. Niaspan, 0.5 to 3.0 g once a night at bedtime, was used alone or in combination with a statin (inhibitor of hydroxymethylglutaryl coenzyme A reductase),
J R, Guyton +5 more
openaire +1 more source
Endocrine Practice, 2012
To observe the effect of the dawn phenomenon on basal glucose and postbreakfast hyperglycemia in patients with type 1 diabetes treated with once-nightly insulin glargine and premeal insulin lispro.In 49 study subjects consuming a fixed isocaloric (50% carbohydrate) diet of usual food, the insulin glargine dose was titrated from daily continuous glucose
Allen B, King +2 more
openaire +2 more sources
To observe the effect of the dawn phenomenon on basal glucose and postbreakfast hyperglycemia in patients with type 1 diabetes treated with once-nightly insulin glargine and premeal insulin lispro.In 49 study subjects consuming a fixed isocaloric (50% carbohydrate) diet of usual food, the insulin glargine dose was titrated from daily continuous glucose
Allen B, King +2 more
openaire +2 more sources
Clinical Neuropharmacology, 2018
Abstract Fluoxetine is a selective serotonin reuptake inhibitor that is commonly used in children and adolescents. Several reports exist regarding the relationship of fluoxetine use and sleep bruxism. We report the case of a 6-year-old girl who was successfully treated with once-nightly dosing of buspirone for fluoxetine-induced sleep bruxism,
Betül, Akbaş, Ayhan, Bilgiç
openaire +2 more sources
Abstract Fluoxetine is a selective serotonin reuptake inhibitor that is commonly used in children and adolescents. Several reports exist regarding the relationship of fluoxetine use and sleep bruxism. We report the case of a 6-year-old girl who was successfully treated with once-nightly dosing of buspirone for fluoxetine-induced sleep bruxism,
Betül, Akbaş, Ayhan, Bilgiç
openaire +2 more sources
Pneumologie (Stuttgart, Germany), 1992
Many patients with asthma often experience a deterioration of symptoms at night and in the early morning resulting in sleep disruption and possibly impaired daily performance. A bronchodilator agent which exerts its maximal effect overnight to control nocturnal symptoms, without a worsening of the disease during the daytime, should improve the ...
V W, Steinijans +4 more
openaire +1 more source
Many patients with asthma often experience a deterioration of symptoms at night and in the early morning resulting in sleep disruption and possibly impaired daily performance. A bronchodilator agent which exerts its maximal effect overnight to control nocturnal symptoms, without a worsening of the disease during the daytime, should improve the ...
V W, Steinijans +4 more
openaire +1 more source
SLEEP
Abstract Introduction Sodium oxybate, available in once-nightly and twice-nightly formulations, is indicated for treatment of cataplexy or excessive daytime sleepiness in narcolepsy. Once-nightly sodium oxybate extended-release oral suspension (ON-SXB; LUMRYZ™) may alleviate potential dosing ...
Maggie Lavender +5 more
openaire +1 more source
Abstract Introduction Sodium oxybate, available in once-nightly and twice-nightly formulations, is indicated for treatment of cataplexy or excessive daytime sleepiness in narcolepsy. Once-nightly sodium oxybate extended-release oral suspension (ON-SXB; LUMRYZ™) may alleviate potential dosing ...
Maggie Lavender +5 more
openaire +1 more source
Long-Term Safety of Once-Nightly Sodium Oxybate: Interim Data From RESTORE
Sleep Medicine, 2022T. Stern +8 more
openaire +1 more source
DOSE TITRATION AND TOLERABILITY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM DATA FROM RESTORE
Chest, 2022ASIM ROY +5 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) or 2 (NT2) in the phase 3 REST-ON trial; treatment with 6, 7.5, and 9 g demonstrated significant improvements vs placebo (all P< 0.001) for the coprimary endpoints of ...
Michael Thorpy +7 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) or 2 (NT2) in the phase 3 REST-ON trial; treatment with 6, 7.5, and 9 g demonstrated significant improvements vs placebo (all P< 0.001) for the coprimary endpoints of ...
Michael Thorpy +7 more
openaire +1 more source
LONG-TERM SAFETY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM ANALYSIS OF DATA FROM RESTORE
Chest, 2022THOMAS P STERN +7 more
openaire +1 more source